The pulmonary function testing systems market size was valued at USD 3.02 billion in 2025 and is projected to grow from USD 3.19 billion in 2026 to USD 5.02 billion by 2034, registering a CAGR of 5.82% during the forecast period (2026–2034). North America dominated the pulmonary function testing systems market with a market share of 42.38% in 2025.
Pulmonary function testing systems are diagnostic devices used to evaluate lung function by measuring airflow, lung volumes, and gas exchange. These systems help diagnose, monitor, and manage respiratory disorders such as asthma, COPD, pulmonary fibrosis, and other lung conditions. Pulmonary function testing systems support early disease detection, treatment planning, and regular assessment of respiratory health.
The pulmonary function testing systems market demand is increasing due to the rising prevalence of respiratory diseases, growing elderly population, and increasing number of pulmonary diagnostic procedures. Healthcare providers are adopting these systems to improve diagnostic accuracy and patient management. Technological advancements and growing awareness of respiratory health are further contributing to pulmonary function testing systems market growth.
Download a Free Sample to Explore Detailed Market Insights
The pulmonary function testing systems market has limited exposure to supply chain disruptions due to diversified manufacturing networks, availability of alternative suppliers, and the non-consumable nature of most diagnostic equipment components. However, disruptions in the supply of electronic components, sensors, semiconductors, and specialized medical device parts have influenced production timelines, inventory management, and equipment availability across global markets. These challenges have encouraged manufacturers to strengthen regional supply chains, increase component sourcing flexibility, and adopt localized production strategies to improve resilience in the healthcare equipment ecosystem. The market is expected to follow a stair-step recovery pattern, supported by gradual supply stabilization, improved manufacturing capacity, and rising demand for respiratory diagnostic systems.
The pulmonary function testing systems market is witnessing a shift toward AI-assisted diagnostic solutions that automate test interpretation and improve accuracy in respiratory assessments. These systems help clinicians analyze complex lung function data faster, reduce variability in interpretation, and support early detection of respiratory disorders. For example, ArtiQ.PFT by ArtiQ applies machine learning algorithms to pulmonary function test data to assist healthcare professionals in identifying respiratory patterns and improving spirometry interpretation consistency. This trend is expected to accelerate as healthcare providers increasingly adopt digital diagnostic tools to enhance workflow efficiency and support more personalized respiratory care.
The pulmonary function testing systems market is moving toward compact, wireless, and cloud connected devices. These systems support remote patient care, home-based testing, and continuous management of chronic respiratory conditions such as COPD and asthma. This trend is gaining momentum as healthcare systems focus on decentralized care models and expanding access to respiratory diagnostics outside clinical environments.
The Pulmonary Function Testing Systems market forecasts sustained investments toward connected respiratory diagnostics, AI-enabled pulmonary assessment, and cloud-based pulmonary function testing platforms. In 2025, Quadrivio Group's Silver Economy Fund acquired 100% of MIR, a leading manufacturer of spirometers and pulmonary function testing systems. The investment supports international expansion, telehealth-enabled respiratory diagnostics, and further development of MIR's connected spirometry and PFT portfolio.
Rising Adoption of Occupational Lung Health Screening Programs and Increasing Clinical Use of Pulmonary Function Testing Before Surgery Drives Market
The increasing implementation of workplace respiratory health programs is driving demand for pulmonary function testing systems as industries focus on early detection of occupational lung disorders. Regulatory requirements for worker health monitoring, especially in industries exposed to airborne hazards, are encouraging organizations to adopt regular spirometry-based assessments. Growing emphasis on preventive occupational healthcare and worker protection is increasing demand for reliable pulmonary function testing systems across industrial health programs.
The expanding use of pulmonary function tests for preoperative evaluation and long-term disease management is increasing demand for advanced testing systems across healthcare facilities. These assessments help physicians evaluate respiratory capacity before major procedures and monitor changes in lung performance among patients with chronic conditions. The growing focus on improving surgical outcomes and personalized respiratory care is supporting wider adoption of pulmonary function testing systems.
Complex Calibration & Maintenance Requirements and Variability in Pulmonary Testing Standards Restrain Market Expansion
Pulmonary function testing systems require regular calibration, sensor validation, and maintenance to ensure measurement accuracy and compliance with clinical standards. Factors such as environmental conditions, equipment aging, and improper maintenance can affect test reliability and increase service requirements. These ongoing technical demands raise operational costs for hospitals and diagnostic centers, particularly smaller facilities with limited technical resources, which can slow adoption of advanced pulmonary testing systems.
Differences in spirometry guidelines, reference values, testing protocols, and interpretation practices across countries create challenges for manufacturers and healthcare providers using pulmonary function testing systems. Equipment must often be configured according to regional clinical standards and population-specific reference equations to ensure accurate results. This lack of uniformity increases implementation complexity for multinational healthcare networks and can delay adoption of standardized pulmonary testing solutions across global markets.
Expansion of Decentralized Respiratory Care and Pediatric Respiratory Diagnostics Offer Growth Opportunities to Market Players
The shift toward home-based respiratory monitoring and decentralized healthcare creates growth opportunities for manufacturers developing portable pulmonary function testing systems. These solutions allow patients with COPD, asthma, and other chronic lung conditions to perform regular assessments outside hospitals while enabling physicians to track disease progression remotely. Companies developing connected spirometry platforms, such as MIR and Vitalograph, can benefit from this trend as healthcare providers increasingly adopt remote monitoring models to reduce hospital visits and improve long-term respiratory management.
The increasing focus on early diagnosis of childhood respiratory disorders creates opportunities for manufacturers developing pediatric-friendly pulmonary function testing systems. Traditional testing methods can be challenging for younger patients due to limited cooperation and breathing technique requirements. Companies offering child-specific solutions, such as incentive-based testing interfaces and adapted spirometry systems, can address this gap as healthcare providers seek more accurate respiratory assessments for pediatric asthma and chronic lung conditions.
Accuracy Limitations in Spirometry and Managing Cross-Compatibility between Disposable Accessories Challenges Market Growth
Spirometers depend heavily on patient cooperation and proper breathing technique, making test accuracy vulnerable to poor maneuver execution, inconsistent effort, and improper device handling. This challenge is more significant in pediatric, elderly, and severely ill patient populations where achieving repeatable measurements can be difficult. Manufacturers must improve usability, coaching features, and automated quality checks to reduce unreliable results and increase confidence among healthcare providers.
Pulmonary function testing procedures often require accessories such as bacterial filters, mouthpieces, flow sensors, and sampling lines that must match specific device platforms. Limited compatibility between consumables and equipment from different manufacturers can increase procurement complexity and operating costs for healthcare providers. This challenge affects purchasing decisions, especially for facilities managing multiple respiratory testing devices and seeking cost-efficient supply management.
The spirometers segment accounted for a share of 43.16% in 2025, owing to widespread adoption in pulmonary diagnostics, precise measurement of forced vital capacity, and extensive use for detecting airflow obstruction. These devices remain preferred due to standardized testing protocols and broad clinical acceptance across respiratory care facilities.
The peak flow meters segment is expected to grow at a CAGR of around 6.43% during the forecast period, driven by the rising home respiratory monitoring demand, increasing asthma management practices, and portable device availability. Their simple operation and frequent usage for tracking peak expiratory flow rates support adoption among patients.
In 2025, chronic obstructive pulmonary disease accounted for a share of 38.49%, as growing COPD prevalence, increasing respiratory screening initiatives, and continuous lung capacity monitoring requirements drive demand. Hospitals utilize these systems for diagnosis, severity assessment, and long-term disease management.
The asthma segment is expected to grow at a CAGR of 6.35% during the forecast period, fueled by increasing asthma incidence, demand for treatment effectiveness evaluation, and rising pediatric respiratory assessments. Pulmonary testing systems support clinicians in monitoring airway changes and optimizing personalized asthma management approaches.
By end user, hospitals & clinics accounted for a share of 46.92% in 2025 due to advanced diagnostic infrastructure, availability of specialized respiratory departments, and higher patient visits for pulmonary evaluations. These facilities widely use testing systems for accurate diagnosis, presurgical assessments, and chronic respiratory condition monitoring.
The homecare settings segment is expected to grow at a CAGR of 7.06% during the forecast period, supported by increasing remote monitoring adoption, demand for compact respiratory devices, and rising elderly patient populations requiring regular assessments. Home-based testing enables convenient lung function tracking and reduces dependence on clinical visits.
North America: Market Dominance Led by Increasing Adoption of Integrated Pulmonary Diagnostic Platforms and Expansion of Tele Respiratory Healthcare Models
The North America pulmonary function testing systems market accounted for the largest regional share of 42.38% in 2025, driven by increasing adoption of integrated pulmonary diagnostic platforms, expansion of connected respiratory monitoring ecosystems, and growing incorporation of pulmonary testing into chronic disease management pathways. The region also benefits from advanced reimbursement frameworks supporting respiratory diagnostics. According to the CDC, more than 16 million US adults were living with chronic obstructive pulmonary disease in 2025, sustaining consistent demand for pulmonary function testing across healthcare settings.
The US pulmonary function testing systems market was valued at USD 1.11 billion in 2025, driven by increasing adoption of advanced spirometry and body plethysmography systems, rising integration of pulmonary diagnostics with electronic health record platforms, and growing demand for automated interpretation technologies. Expansion of outpatient pulmonary laboratories and increasing preference for efficient respiratory assessment workflows are strengthening market adoption.
The pulmonary function testing systems market in Canada was valued at USD 166.42 million in 2025, supported by increasing deployment of portable respiratory testing solutions, expansion of tele respiratory healthcare models, and demand for diagnostic accessibility across remote regions. Healthcare systems are prioritizing decentralized pulmonary assessment capabilities to improve service reach.
Asia Pacific: Fastest Growth Driven by Increasing Deployment of Respiratory Diagnostic Infrastructure and Growing Demand for Advanced Testing Solutions
The Asia Pacific pulmonary function testing systems market is expected to grow at a CAGR of 7.40% during the forecast period, showcasing the fastest regional growth. Growth is driven by increasing deployment of respiratory diagnostic infrastructure in emerging healthcare markets, rising adoption of compact pulmonary testing devices for decentralized care, and growing integration of digital respiratory monitoring solutions. The region is witnessing stronger demand for affordable and scalable diagnostic technologies as healthcare providers improve access to respiratory assessments beyond major metropolitan centers.
The China pulmonary function testing systems market size was valued at USD 167.96 million in 2025, supported by increasing installation of pulmonary laboratories in county-level hospitals, rising adoption of automated lung function testing platforms, and growing standardization of respiratory diagnostic procedures across healthcare facilities. Expansion of public healthcare capacity and modernization of regional medical centers are supporting wider availability of advanced pulmonary assessment technologies beyond major urban hospitals.
The India pulmonary function testing systems market size was valued at USD 85.91 million in 2025, fueled by increasing adoption of AI-assisted respiratory analysis tools, rising integration of pulmonary diagnostics within multispecialty hospitals, and growing demand for advanced testing solutions for occupational and environmental respiratory conditions. Expansion of preventive health screening programs and increasing focus on early respiratory risk identification are supporting market growth.
The Japan pulmonary function testing systems market was valued at USD 99.12 million in 2025, propelled by increasing utilization of precision respiratory assessment technologies, rising demand for automated pulmonary diagnostics in aging care settings, and the integration of advanced testing systems within preventive healthcare programs. The country’s emphasis on early functional decline detection and technology-driven healthcare delivery is accelerating adoption of sophisticated pulmonary function testing solutions across medical institutions.
The pulmonary function testing systems market competitive landscape is moderately consolidated, with competition driven by established diagnostic equipment manufacturers specializing in respiratory care, pulmonary diagnostics, and connected healthcare solutions. Leading players compete through advancements in measurement accuracy, digital connectivity, automated interpretation, and device portability. Emerging companies focus on AI-based analysis, home-based monitoring, and affordable testing solutions to expand access. The pulmonary function testing systems market ecosystem is shaped by rising respiratory disease burden, evolving diagnostic practices, and technology adoption.
June 2026: COSMED signed an agreement to acquire a majority stake in MADA, expanding its cardiopulmonary diagnostic and pulmonary function testing portfolio.
May 2026: ndd Medical Technologies introduced nddHub, a cloud-based digital platform designed to support EasyOne spirometry workflows, data management, and connectivity across healthcare providers.
February 2026: ndd Medical Technologies achieved HITRUST e1 Certification for cybersecurity and information protection.
October 2025: ndd Medical Technologies participated in CHEST 2025, showcasing its EasyOne pulmonary function testing portfolio.
September 2025: Lungpacer Medical received FDA PMA supplement approval for software updates to the AeroPace System.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com